欧洲泌尿外科学会肾癌指南:2019 年更新版。

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.

机构信息

Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.

Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

出版信息

Eur Urol. 2019 May;75(5):799-810. doi: 10.1016/j.eururo.2019.02.011. Epub 2019 Feb 23.

Abstract

CONTEXT

The European Association of Urology Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management of RCC.

OBJECTIVE

To provide an updated RCC guideline based on standardised methodology including systematic reviews, which is robust, transparent, reproducible, and reliable.

EVIDENCE ACQUISITION

For the 2019 update, evidence synthesis was undertaken based on a comprehensive and structured literature assessment for new and relevant data. Where necessary, formal systematic reviews adhering to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were undertaken. Relevant databases (Medline, Cochrane Libraries, trial registries, conference proceedings) were searched until June 2018, including randomised controlled trials (RCTs) and retrospective or controlled studies with a comparator arm, systematic reviews, and meta-analyses. Where relevant, risk of bias (RoB) assessment, and qualitative and quantitative syntheses of the evidence were performed. The remaining sections of the document were updated following a structured literature assessment. Clinical practice recommendations were developed and issued based on the modified GRADE framework.

EVIDENCE SYNTHESIS

All chapters of the RCC guidelines were updated based on a structured literature assessment, for prioritised topics based on the availability of robust data. For RCTs, RoB was low across studies. For most non-RCTs, clinical and methodological heterogeneity prevented pooling of data. The majority of included studies were retrospective with matched or unmatched cohorts, based on single- or multi-institutional data or national registries. The exception was for the treatment of metastatic RCC, for which there were several large RCTs, resulting in recommendations based on higher levels of evidence.

CONCLUSIONS

The 2019 RCC guidelines have been updated by the multidisciplinary panel using the highest methodological standards. These guidelines provide the most reliable contemporary evidence base for the management of RCC in 2019.

PATIENT SUMMARY

The European Association of Urology Renal Cell Carcinoma Guideline Panel has thoroughly evaluated the available research data on kidney cancer to establish international standards for the care of kidney cancer patients.

摘要

背景

欧洲泌尿外科学会(EAU)肾癌(RCC)指南小组制定了基于循证医学的 RCC 管理指南和建议。

目的

采用系统评价等标准化方法提供更新的 RCC 指南,确保其具有稳健性、透明性、可重复性和可靠性。

证据获取

在 2019 年更新中,根据对新的和相关数据的全面和结构化文献评估进行证据综合。在必要时,按照系统评价和荟萃分析的首选报告项目(PRISMA)指南进行正式的系统评价。检索了相关数据库(Medline、Cochrane 图书馆、试验登记处、会议论文集),检索时间截至 2018 年 6 月,包括随机对照试验(RCT)和具有对照臂的回顾性或对照研究、系统评价和荟萃分析。在相关情况下,对风险偏倚(RoB)进行评估,并对证据进行定性和定量综合。文件的其余部分根据结构化文献评估进行了更新。根据改良的 GRADE 框架制定和发布临床实践建议。

证据综合

根据对基于现有数据的优先主题的结构化文献评估,更新了 RCC 指南的所有章节。对于 RCT,研究的 RoB 较低。对于大多数非 RCT,临床和方法学异质性阻止了数据的合并。大多数纳入的研究是回顾性的,基于单一或多机构数据或国家登记处,具有匹配或不匹配的队列。转移性 RCC 的治疗除外,因为有几项大型 RCT,从而基于更高水平的证据提出了建议。

结论

多学科小组使用最高的方法学标准更新了 2019 年 RCC 指南。这些指南为 2019 年 RCC 的管理提供了最可靠的当代循证基础。

患者总结

欧洲泌尿外科学会肾癌指南小组彻底评估了肾脏癌症的现有研究数据,为肾脏癌症患者的护理建立了国际标准。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索